WILMINGTON, N.C. & WINSTON-SALEM, N.C., July 11, 2012 /PRNewswire/ -- Inclinix-PMG Holdings, a global clinical trial site and patient recruitment organization, today announced changes to the executive management team.
Dr. John Rubino of Raleigh Medical Group (RMG) has been appointed Medical Director of Inclinix-PMG Holdings, Inc. and also will serve as the head of the Principal Investigator Advisory Board. Dr. Rubino has been actively involved in clinical research for the past 22 years, and has been a Principal Investigator in over 600 trials. He was instrumental in developing clinical research in association with RMG and will lend his experience and expertise in clinical research to the Inclinix-PMG Holdings organization. Dr. Rubino says, "I look forward to helping meld the strengths of both Inclinix and PMG into the premier research organization by focusing on making our research efforts a win for patients, physicians and our research sponsors."
Jennifer Byrne has been named President and Chief Operating Officer of PMG Research Inc. Ms. Byrne has 25 years experience in the clinical research field. Through her various management roles, she has been influential in guiding the development and growth of PMG Research for the past 20 years, and will continue to do so in this capacity.
Denise Robinson has been named President and Chief Operating Officer of Inclinix, Inc. Ms. Robinson has over 15 years of pharmaceutical, clinical and healthcare experience. She has served in multiple leadership roles with Inclinix in her 10-year tenure and her experience and insight will provide valuable strategic direction for Inclinix.
"Together Inclinix and PMG Research bring forth an unrivaled precedent for research site-based experience which will allow for better outcomes for pharmaceutical sponsors, physician investigators, and research participants," says Ms. Byrne. Denise Robinson explains, "This merger is the great outcome of years of successful enrollment experience focused on supporting clinical research sites with innovative and effective patient recruitment solutions."
"It is exciting to have this level of experience and industry knowledge leading the Inclinix and PMG Research divisions. We also are privileged to have the medical direction of Dr. Rubino supporting our efforts to make clinical trials a trusted treatment option for patients and physicians," states Inclinix-PMG Holdings, Inc. President and CEO, J. Tobin Geatz.
Inclinix-PMG Holdings, Inc. was formed by the strategic merger of Inclinix, Inc. with PMG Research Inc. in June 2012 with the vision to improve lives globally by making clinical trials a trusted treatment option for patients and physicians. Inclinix-PMG Holdings, Inc. strives to make clinical trials more available, accessible, and efficient with a commitment to Quality, Innovation, Integrity, and Community.
About PMG Research
PMG Research, Inc. is an Integrated Site Network based in Winston-Salem, NC. The staff and physicians at PMG Research have contributed to the development of numerous medications, medical devices and vaccines. PMG's mission is to provide unparalleled service to their clinical trial participants and pharmaceutical sponsors. www.pmg-research.com
Inclinix, Inc. is a clinical trial enrollment solutions provider for pharmaceutical, biotechnology and medical device organizations based in Wilmington, NC. Clients benefit from twelve years of experience in multiple therapeutic areas. Inclinix delivers a customized, site-focused approach to patient recruitment ensuring every available study candidate is identified, qualified and enrolled. By combining an in-field approach with highly targeted patient outreach, Inclinix creates effective enrollment strategies within a performance model. www.inclinix.com
|SOURCE Inclinix-PMG Holdings, Inc.|
Copyright©2012 PR Newswire.
All rights reserved